thirdly, 8-anilino-naphtalene-sulphonic (ANS) acid does not inhibit thyroid hormone binding to both IgG and lipoproteins-; fourthly, even in animals, false positive results for T3-Ab were observed in lipemic sera'', Accordingly, plasma lipoprotein levels should be given. Anyway, specific radioimmunoprecipitation with anti-human-IgG serum is the reliable method.
(2) Table 3: Analysis of this table makes even less convincing the presence of T4-Ab in patient A. At variance with the literature", in fact, are the supranormal levels of FT4 and normal levels of TI'4 in a euthyroid subject. The methods employed (the unaffected, by THAb, equilibrium dialysis for FT4 and the affected double-antibody RIA for TI'4) would have produced normal FT4 and, as occurred in patient B, supranormal TI4. The possibility, however, exists that the high FT4 was produced by the circulating inhibitors of the thyroid hormone binding to serum proteins frequently observed in non-thyroid illnessess.
(3) Prevalence: Taking into account the case ofT3·Ab mentioned in the discussion in the paper by Farror et al., the prevalence of THAb in the general population is 0.0003% (3/1000000). If we exclude the small series (n=182) by Merlin et al. 6 , in the other 3 available studies? the prevalence is 167 to 666 times greater. The difference is even more impressive, because the authors! used a method overestimating the frequency of detection of THAb.
(4) Specificity: Although cross-reactivity was not tested, we can deduce that two patients (2/3,75%) had THAb to T4 only and one (25%) to T3 only. Instead, THAb frequently cross-react (T3+T4±tT3) and, anyway, T3Ab are by far more frequent than T4-Ab 4 • Finally, in view of the readership of the Journal, we would like to stress that THAb are, in all probability, Ab to thyroglobulin cross-reacting with thyroid hormones and that they per se do not call for any treatment", S BENVENGA The authors reply below * Sir, We thank Dr Benvenga for his letter and for the further information he provides to your readers, including ourselves, on the methods of testing for thyroid antibodies. We agree that radioimmune precipitation with the specific anti-human-sera-IgG is theoretically a more specific method for detecting the autoantibodies than the method we used based on non-specific binding of labelled T4 or T3 in barbitone in the presence of excess blocker followed by polyethylene glycol separation. Nevertheless, the method we chose is practical, sensitive and suitable for our type of diagnostic laboratory as a screen for false positives caused by T4 or T3 antibodies. We agree that the yearly incidence of such autoantibodies are likely to be much higher than Dr Benvenga has deduced from our figures and this point is made in the last paragraph of our paper. The specimens from other patients (including the four with FDH) were referred from other hospitals in Adelaide.
Certainly, we agree that patients or individuals with this type of anomaly and with FDH must not be treated for thyroid dysfunction, this being the purpose of our paper, and our last two sentences state this clearly. Rippere has drawn attention to the possible underreporting of adverse reactions to pharmaceutical excipients. An example is given of a patient who made a recovery after having been transferred from an, orange and white anticonvulsant to an equivalent generic product.
Although the anticonvulsant concerned was not named, it seems likely that it was Epanutin. I would firstly like to make it clear that Epanutin no longer contains tartrazine which has been replaced by another dye. Secondly, may I emphasize that phenytoin, the active principal within Epanutin capsules, has a complex pharmacokinetic profile and a long history ofbioavailability differences from one
